A Prescription Drug User Fee Act target date of September 14, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) ...

A Prescription Drug User Fee Act target date of September 14, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application ...

AFRIN ORIGINAL- oxymetazoline hydrochloride spray. Harvard Medical School, Harvard Health Publishing. Don't let decongestants squeeze your heart. Mortuaire G, De Gabory L, François M, et al. Rebound ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

In “Cerebral Entanglements,” Allan J. Hamilton argues that new imaging technologies give us unprecedented access — with revolutionary implications. By Deborah Blum “Saturday Night Live ...

22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder ... Approval of Spravato, ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment ...

A doctor may prescribe ketorolac (Toradol), an NSAID available as a nasal spray, to help manage migraine attacks that cause severe pain. They may also recommend ketorolac as a rescue medication if ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions ... granted following FDA priority review, comes after more than a decade of ...

Every Friday, be the first to see reviews, news and features in The New York Times Book Review.